74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Fresenius SE & Co KGaA
Open
SectorHealthcare
40.01 0.5
Overview
Share price change
24h
Min
39.7
Max
40.03
Income | -48M 271M |
|---|---|
Sales | 264M 5.6B |
P/E Sector Avg | 24.381 57.333 |
Profit margin | 4.813 |
Employees | 176,486 |
EBITDA | -33M 724M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +17.39% upside |
Next Earnings | 7 May 2025 |
|---|
Market Cap | 1.1B 22B |
|---|---|
Previous open | 39.51 |
Previous close | 40.01 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
Fresenius SE & Co KGaA Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Fresenius SE & Co KGaA Forecast
Price Target
By TipRanks
17.39% upside
12 Months Forecast
Average 46.78 EUR 17.39%
High 56.9 EUR
Low 42 EUR
Based on 13 Wall Street analysts offering 12 month price targets forFresenius SE & Co KGaA - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Fresenius SE & Co KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
